BetaKine Shows Promise in Treating Macular Holes

Strategic Insights -

Data presented at the American Academy of Ophthalmology meeting in San Francisco showed that BetaKine, a therapeutic agent developed by Celtrix Pharmaceuticals, demonstrated significant efficacy in treating patients with macular holes, a retinal condition that causes loss of central vision. The study, conducted at the Bascom Palmer Eye Institute and the Retina Institute of Maryland, found that 83% of patients showed macular hole flattening and 52% showed vision improvement of three lines or better. These results offer hope for patients who have failed previous ophthalmic surgery.

Key Takeaways:

  • BetaKine showed significant efficacy in treating macular holes, with 83% of patients showing macular hole flattening and 52% showing vision improvement of three lines or better.
  • The study was conducted at the Bascom Palmer Eye Institute and the Retina Institute of Maryland, and included 48 eyes with previously failed ophthalmic surgery.
  • 54% of patients achieved final vision of 20/63 or better, which is sufficient for driving a car and enjoying a normal, active lifestyle.
  • The study demonstrates the potential of BetaKine to treat ophthalmic disorders, in addition to its previously reported prospects for cancer-related diseases and other major medical problems.
  • Celtrix is a biopharmaceutical company focused on the treatment of seriously debilitating, degenerative conditions primarily associated with aging or chronic diseases.
  • Patient participants had previously received either vitrectomy with no drug therapy or vitrectomy and BetaKine, primarily the low dose used in earlier clinical studies.

Statistics:

  • 83% of patients (40 eyes) showed macular hole flattening
  • 52% of patients (25 eyes) showed vision improvement of three lines or better
  • 54% of patients (26 eyes) achieved final vision of 20/63 or better
  • 48 eyes received repeat surgery plus BetaKine, and were followed for an average of seven months post-therapy

Sources:

  • BUSINESS WIRE, "Celtrix Pharmaceuticals Provides Update on BetaKine(TM) Development and Reports 1993 Third Quarter Results," November 1, 1994
  • Celtrix Pharmaceuticals Inc.